Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 2001, p. 353-355, Vol. 45, No. 1
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.1.353-355.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
In Vitro Pharmacodynamic Studies of Activities of
Ketolides HMR 3647 (Telithromycin) and HMR 3004 against Extracellular
or Intracellular Helicobacter pylori
I.
Gustafsson,1
L.
Engstrand,1 and
O.
Cars2,*
Department of Clinical
Bacteriology,1 and Antibiotic Research
Unit, Department of Infectious Diseases,2
Uppsala University, Uppsala, Sweden
Received 24 April 2000/Returned for modification 21 August
2000/Accepted 25 October 2000
 |
ABSTRACT |
The pharmacodynamic properties of the ketolides HMR 3647 (telithromycin) and HMR 3004 were studied against Helicobacter
pylori. Both ketolides showed a pronounced
concentration-dependent killing, a significant postantibiotic effect, a
long postantibiotic sub-MIC effect, and a reduction of intracellular
H. pylori.
 |
TEXT |
Helicobacter pylori
establishes persistent infection in the gastric mucosa of humans.
Antimicrobial treatment of H. pylori is now widely
recommended for patients with peptic ulcer who are carrying this
bacterium. H. pylori has so far been considered to colonize
exclusively extracellularly. There are, however, considerable data
supporting an intracellular location of the bacterium in vivo (4,
8). Due to the increasing problems with macrolide resistance in
H. pylori (5, 9), the development of new
treatment regimens, including antibiotics with intracellular activity,
is needed. The aim of our study was to evaluate the pharmacodynamic properties of the ketolides HMR 3647 (telithromycin) and HMR 3004 against extracellular and intracellular H. pylori.
(This work was presented at the 38th Interscience Conference on
Antimicrobial Agents and Chemotherapy, San Diego, Calif., 24 to 27 September, 1998.)
H. pylori NCTC 11637 was grown on chocolate agar plates
(Columbia II agar base BBL; Becton Dickinson and Co., Franklin Lake, N.J.) supplemented with 10% horse serum and 8.5% horse blood. For
broth cultures we used brucella broth (pH 7.3) supplemented with 10%
fetal calf serum. Plates and broth cultures were incubated at 37°C in
a humid atmosphere under microaerophilic conditions (7%
CO2 and 87% N2). Broth cultures, incubated for
3 days, were prepared prior to the experiments. The turbidity was
measured at an optical density at 530 nm of 0.5, which corresponds to
108 CFU/ml. HMR 3647 and HMR 3004 with known potencies were
kindly provided by Hoechst Marion Roussel, Romainville, France. A stock solution was made before each experiment by dissolving 10.2 mg of the
drug in 10 ml of sterile distilled water supplemented with 20 µl of
glacial acetic acid.
MICs were determined by the macrodilution technique with an inoculum of
5 × 105 to 1 × 106 CFU/ml,
according to NCCLS standards (11). The MIC was defined as
the lowest concentration inhibiting visible growth after 3 days. To
investigate whether the killing pattern was concentration dependent,
bacteria at a density of 106 CFU/ml were exposed to 2, 5, 10, and 50 times the MIC. A growth control was also included. Samples
were withdrawn after 0, 1, 2, 3, 6, 9, 12, and 24 h, and
appropriate dilutions were seeded on chocolate agar in volumes of 0.1 and 0.01 ml. The plates were incubated for 5 days before the colonies
were counted. The sensitivity of the viable count is estimated at 10 to
50 CFU/ml.
Postantibiotic effect (PAE) and postantibiotic sub-MIC effect (PASME)
determinations were performed with cultures of 107 CFU/ml
exposed to 10 times the MIC for 2 h at 37°C. Unexposed controls
were included. To eliminate the antibiotics, both cultures were washed
twice with broth by centrifugation for 10 min at 1,400 × g and then diluted in fresh broth to obtain 104
CFU/ml. The bacterial culture in the postantibiotic phase was divided
into three tubes, of which two tubes were reexposed to subinhibitory
concentrations of 0.1 and 0.3 times the MIC. Regrowth was followed by
viable count at the start, before and after the wash, and after 4, 6, 8, 11, 24, 48, and 72 h. The PAE and PASME were defined according
to the following formula: TPA
C, where TPA is the time required for
the count for previously exposed cultures to increase by 1 log10 unit above the count observed immediately after the
wash. C is the corresponding time for the unexposed control.
The experiments were done in triplicate.
Intracellular activity was studied in a human epithelial cell line,
HEp-2 (ATCC CCL 23). The cell culture medium (pH 7.2) contained RPMI
1640 (Gibco BRL Life Technologies, Paisley, Scotland), 10% fetal calf
serum, 20 mM HEPES, 2 mM glutamine, and 0.05% NaHCO3. The
cells were treated with trypsin, seeded into cell culture inserts with
pores measuring 0.45 µm (Becton Dickinson) at a density of
105 cells/ml, and incubated at 35°C with 5%
CO2. Monolayers of HEp-2 cells were exposed to
106 CFU of H. pylori/ml suspended in cell medium
and allowed to internalize for 9 h at 35°C with 5%
CO2. Extracellular bacteria were eradicated by washing the
wells five times with medium containing 50 mg of gentamicin (Roussel,
Denham Uxbridge, United Kingdom) per liter, followed by incubation for
2 h in the same medium. To verify that the extracellular H. pylori had been eradicated, samples were plated onto chocolate
agar. The cell culture inserts fit into a specially constructed in
vitro kinetic apparatus (7). Briefly, it consisted of a
glass chamber with two exits, which connects to a pump (C6-T; Alitea
AB, Stockholm, Sweden). A metal rack for the inserts was placed in the
chamber, and a magnet ensured homogenous mixing. Cell culture medium,
supplemented with 0.03 M glucose and 0.0001% cycloheximide (Sigma, St.
Louis, Mo.), and the antibiotics at a concentration of 10 times the MIC
were added into the glass chamber and inserts. The flow rate was set to
achieve a half-life inside the inserts of approximately 12 h,
which corresponds to the kinetics in humans. The device was placed on a
magnetic stirrer standing in a thermostat set at 35°C with 5%
CO2. Controls without antibiotics were grown simultaneously
in a companion tissue culture plate. After 0, 2, 4, 8, and 24 h,
inserts were collected for viable counts and determination of
antibiotic concentration. The cells were washed three times with
phosphate-buffered saline, removed from the membranes by gentle
scraping with a transfer pipette, and lysed with distilled water for 10 min. After 5 min of centrifugation at 10,000 × g, the
pellets were dissolved in 1 ml of brucella broth and plated on
chocolate agar as described above. The experiments were done in triplicate.
The antibiotic concentration was determined in the media from both the
glass chamber and the inserts before cell lysis. A microbiological agar
diffusion method was used with tryptone-glucose agar (pH 7.4). Plates
were seeded with a standardized inoculum of Sarcina lutea.
Antibiotic standards and samples were placed into agar wells at a
volume of 0.03 ml. All assays were done in triplicate, and the plates
were incubated overnight at 37°C. The limit of detection was 0.03 mg/liter, and the correlation coefficient for the standard curves was
always >0.99.
The MIC for H. pylori NCTC 11637 was 0.5 and 0.125 mg/liter
for HMR 3647 and HMR 3004, respectively. A pronounced
concentration-dependent killing was found with both ketolides. For HMR
3647, a bactericidal effect of 3 log10 was seen within
3 h for 50 times the MIC, within 6 h for 10 and 5 times the
MIC, and within 12 h for 2 times the MIC (Fig.
1). For HMR 3004, the bactericidal effect
was achieved at 6 h with 50 times the MIC and at 12 h with 10 times the MIC. At the lower concentrations of 5 and 2 times the MIC,
the reduction was 2 log10 after 24 h. The PAEs for HMR
3647 and HMR 3004 were 13 h (range, 8 to 22 h) and 6 h
(range, 5 to 33 h), respectively. Addition of a subinhibitory
concentration of 0.1 times the MIC in the postantibiotic phase yielded
long PASMEs ranging from 24 to >48 h for HMR 3647 and 12 h for
HMR 3004. At the concentration of 0.3 times the MIC, no regrowth could
be detected within 72 h for either of the ketolides.
The antibiotic concentration within the culture inserts is presented in
Fig. 2a. The mean half-life was
determined to be 13 h (range, 6.5 to 16.6 h). The experiments
were limited to 8 h since the number of viable bacteria in the
controls then declined. Therefore, the effect of subinhibitory
concentrations could not be studied in these experiments. The
intracellular killing during 8 h was 2 log10 for HMR
3647 (Fig. 2b) and 1.8 log10 for HMR 3004.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
(a) Concentration curve for HMR 3004. Bars indicate
standard deviations. (b) Intracellular H. pylori exposed to
10 times the MIC of HMR 3647. Bars indicate standard deviations.
|
|
The ketolide HMR 3647 (telithromycin) belongs to a new class of
macrolides and is presently in clinical development. Although earlier
macrolides exhibit a long PAE, their antibacterial activity is not
usually concentration dependent and the major determinant of killing is
the duration of free drug concentrations above the MIC
(2). The pharmacodynamics of the ketolides is less well known. However, a significant PAE and PASME have been demonstrated (1; I. Odenholt, E. Löwdin, and O. Cars,
Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr.
A-540, 1999), as has concentration-dependent killing (W. A. Craig
and D. R. Andes, Abstr. 40th Intersci. Conf. Antimicrob. Agents
Chemother., abstr. 2141, 2000). Our study showed a clear
concentration-dependent killing of H. pylori. Sörberg
et al. demonstrated a long PAE of approximately 15 h for H. pylori after exposure to 10 times the MIC of clarithromycin for
5 h (13). We experienced a wide range of PAEs between
the experiments, from 8 to 22 h. Pharmacodynamic studies on
H. pylori pose technical difficulties, and even with optimal
technical conditions the growth rate sometimes alters. In broth
cultures the bacteria turn into a coccoid form after a period of time
(3). The coccoid form is metabolically inactive, and it is
not yet known what triggers the transformation. The delayed regrowth in
the PAE experiments thus may be due not only to the antibiotic
exposure. However, with exposure to a sub-MIC concentration of 0.1 times the MIC after preexposure to 10 times the MIC for only 2 h,
the reductions in bacteria were similar to those following the static
exposure to 10 times the MIC for 24 h. The subinhibitory
concentration was obviously sufficient to maintain a critical
concentration of drug at the site of the ribosomes. This could be
explained by the fact that ketolides form a strong complex with 23S
rRNA (6). This pronounced effect of subinhibitory
concentrations corresponds well with results from studies on macrolides
and azithromycin, in which long PASMEs have been described
(12). Pharmacodynamic studies are often performed under
static conditions, but it is important to include kinetic models. We
have previously developed a kinetic method for intracellular pathogens
that was found to be useful in an initial screening phase of drug
evaluation. HMR 3647 and HMR 3004 are rapidly accumulated in HEP-2
cells, with an intracellular/extracellular ratio of about 10 (14, 15; I. Garcia, A. Pascual, S. Ballesta, and
E. J. Perrera, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-112, 1998). The theory of intracellular H. pylori is still controversial but it seems that the bacteria can hide within the epithelial cells of the mucosa. This has been revealed
by electron microscopy and by time-lapse photography (4,
10). In the present study a fairly constant amount of intracellular bacteria was obtained in the controls for 8 h.
During this period both HMR 3647 and HMR 3004 exhibited 1.8 to 2 log10 reductions of bacteria, and the effect on
intracellular H. pylori was evident. This new group of
ketolide antibiotics seems to be promising for treatment of
extracellular and intracellular H. pylori.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from Hoechst Marion Roussel,
Romainville, France.
We thank Tord Nyström for excellent technical assistance.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Infectious Diseases, University Hospital, SE-751 85 Uppsala, Sweden. Phone: 46 (18) 611 56 72. Fax: 46 (18) 611 56 50. E-mail:
otto.cars{at}smi.ki.se.
 |
REFERENCES |
| 1.
|
Boswell, F. J.,
J. M. Andrews, and R. Wise.
1998.
Pharmacodynamic properties of HMR 3647, a new ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect.
J. Antimicrob. Chemother.
41:149-153[Abstract/Free Full Text].
|
| 2.
|
Craig, W. A.
1998.
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.
Clin. Infect. Dis.
26:1-12[Medline].
|
| 3.
|
Enroth, H.,
K. Wreiber,
R. Rigo,
D. Risberg,
A. Uribe, and L. Engstrand.
1999.
In vitro aging of Helicobacter pylori: changes in morphology, intracellular composition and surface properties.
Helicobacter
4:7-16[CrossRef][Medline].
|
| 4.
|
Evans, D. G.,
D. J. Evans, Jr., and D. Y. Graham.
1992.
Adherence and internalization of Helicobacter pylori by HEp-2 cells.
Gastroenterology
102:1557-1567[Medline].
|
| 5.
|
Glupczynski, Y.,
A. Burette,
V. Lamy, and M. G. Garrino.
1998.
Evolution of H. pylori primary resistance to antimicrobial agents in Belgium between 1995 and 1998.
Gut
43(Suppl. 2):A48.
|
| 6.
|
Hansen, L. H.,
P. Mauvais, and S. Douthwaite.
1999.
The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA.
Mol. Microbiol.
31:623-631[CrossRef][Medline].
|
| 7.
|
Hultén, K.,
R. Rigo,
I. Gustafsson, and L. Engstrand.
1996.
New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms.
Antimicrob. Agents Chemother.
40:2727-2731[Abstract].
|
| 8.
|
Hultén, K.
1997.
Helicobacter pylori: transmission, survival and eradication. Ph.D. dissertation.
Uppsala University, Uppsala, Sweden.
|
| 9.
|
Hultén, K.,
B. Jaup,
B. Stenquist, and L. Engstrand.
1997.
Combination treatment with ranitidine is highly efficient against Helicobacter pylori despite negative impact of macrolide resistance.
Helicobacter
2:188-193[Medline].
|
| 10.
|
Löfman, C.,
R. Rigo,
M. Block,
K. Hultén,
H. Enroth, and L. Engstrand.
1997.
Bacterium-host interactions monitored by time-lapse photography.
Nat. Med.
3:930-931[CrossRef][Medline].
|
| 11.
|
National Committee for Clinical Laboratory Standards.
1998.
Methods for determining bactericidal activity of antimicrobial agents. Tentative guideline M100-S8.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 12.
|
Odenholt-Tornqvist, I.,
E. Löwdin, and O. Cars.
1995.
Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens.
Antimicrob. Agents Chemother.
39:221-226[Abstract].
|
| 13.
|
Sörberg, M.,
H. Hanberger,
M. Nilsson, and L. E. Nilsson.
1997.
Pharmacodynamic effects of antibiotics and acid pump inhibitors on Helicobacter pylori.
Antimicrob. Agents Chemother.
41:2218-2223[Abstract].
|
| 14.
|
Vazifeh, D.,
H. Abdelghaffar, and M. T. Labro.
1997.
Cellular accumulation of the ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin.
Antimicrob. Agents Chemother.
41:2099-2107[Abstract].
|
| 15.
|
Vazifeh, D.,
A. Preira,
A. Bryskier, and M. T. Labro.
1998.
Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils.
Antimicrob. Agents Chemother.
42:1944-1951[Abstract/Free Full Text].
|
Antimicrobial Agents and Chemotherapy, January 2001, p. 353-355, Vol. 45, No. 1
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.1.353-355.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Jodlowski, T. Z, Lam, S., Ashby, C. R Jr
(2008). Emerging Therapies for the Treatment of Helicobacter pylori Infections. The Annals of Pharmacotherapy
42: 1621-1639
[Abstract]
[Full Text]
-
Yanagihara, K., Morinaga, Y., Nakamura, S., Seki, M., Izumikawa, K., Kakeya, H., Yamamoto, Y., Yamada, Y., Kamihira, S., Kohno, S.
(2008). Subinhibitory concentrations of telithromycin, clarithromycin and azithromycin reduce methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo. J Antimicrob Chemother
61: 647-650
[Abstract]
[Full Text]
-
Ackermann, G., Rodloff, A. C.
(2003). Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide. J Antimicrob Chemother
51: 497-511
[Abstract]
[Full Text]
-
Fahey, J. W., Haristoy, X., Dolan, P. M., Kensler, T. W., Scholtus, I., Stephenson, K. K., Talalay, P., Lozniewski, A.
(2002). Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl. Acad. Sci. USA
99: 7610-7615
[Abstract]
[Full Text]